深圳市海王英特龍生物技術股份有限公司
SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED*
(a joint stock limited company incorporated in the People's Republic of China)
(Stock Code: 8329)

INSIDE INFORMATION ANNOUNCEMENT

This announcement is made by Shenzhen Neptunus Interlong Bio-technique Company Limited* (the "**Company**" and together with its subsidiaries, the "**Group**") pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the "**GEM Listing Rules**") and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company is pleased to announce that the Company proposes to acquire certain equity of Shenzhen GeneBioHealth Co., Ltd. ("**GeneBioHealth**") via issuance of new shares or transfer of existing shares, and conduct relevant operations by leveraging sales resources of the Company's holding company and products developed by GeneBioHealth's proprietary platform. The Company expects that the cooperation is able to extend the Group's industrial chain and expand its market, thereby developing new growth drivers for the Group's future development. The Company will consider a further increase in its shareholding, if the cooperation proceeds successfully and GeneBioHealth's business develops smoothly.

GeneBioHealth is a sino-foreign joint venture, registered in Shenzhen, Guangdong, the PRC, with a registered capital of RMB15,028,237.47. GeneBioHealth specializes in the field of early diagnosis and screening of tumor, possesses a full industrial chain covering the research and development, manufacturing, sales of diagnostic reagent and instruments, as well as third-party medical testing. It is capable of providing comprehensive solutions including technology, reagent, instrument and service for tumor diagnosis. GeneBioHealth owns miRNA (microRNA) technology platform, and offers China's first colorectal cancer diagnostic product based on miRNA technology. The product is also China's first Class III medical device for colorectal cancer genetic diagnosis. At present, GeneBioHealth has over 10 in-house and licensed invention patents both domestically and internationally, and its diagnostic products for colorectal cancer, gastric cancer and nasopharyngeal carcinoma have obtained EU CE certification, while diagnostic products for other high-incidence cancers such as breast cancer, pancreatic cancer, prostate cancer, bladder cancer and pan-cancer are continuously under development.

As at the date of this announcement, the Company has entered into a letter of intent regarding the aforementioned potential investment, however, no legally binding investment agreement has been entered into. The parties are currently engaged in arm's length discussion regarding the relevant details. Should the aforementioned potential investment and cooperation be proceeded, disclosure in relation to relevant progress will be made by the Company as and when appropriate in accordance with the GEM Listing Rules.

Shareholders and/or investors of the Company should note that the letter of intent is intended to set forth the parties' preliminary intentions regarding the investment. The letter of intent is a non-legally binding agreement, and does not impose any legal obligations on any of the parties in any respect. As the parties has not yet executed any formally binding documents and negotiation is still ongoing, the investment under the letter of intent may or may not be proceeded. Shareholders and/or investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Shenzhen Neptunus Interlong Bio-technique Company Limited*
Zhang Feng
Chairman

Shenzhen, the PRC, 25 June 2026

As at the date of this announcement, the executive Directors are Mr. Zhang Feng, Mr. Huang Jian Bo and Mr. Zhang Xiao Guang; the non-executive Directors are Mr. Zhang Yi Fei, Mr. Jin Rui and Mr. Zhang Xiao Peng; and the independent non-executive Directors are Mr. Yick Wing Fat, Simon, Mr. Poon Ka Yeung and Ms. Zhu Jia Min.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from its date of publication and on the Company's website at www.interlong.com.

* *For identification purpose only*